- This rare genetic disease currently lacks FDA-approved treatments, making the submission a significant milestone. Plozasiran, also known as ARO-APOC3, is an investigational RNA interference (RNAi) therapeutic. It aims The post Arrowhead...
- The FDA has set a target action date of 18 April 2025 for its decision. If approved, Dupixent is expected to become the first targeted CSU therapy in The post FDA to review Sanofi, Regeneron’s Dupixent sBLA for CSU appeared first on...
- Under the agreement, Kaken has secured an option to acquire commercial rights to the antibody in select Asian territories. In return, the company will fund the preclinical and The post Numab Therapeutics and Kaken Pharmaceutical...
- A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence the progression of neurodegeneration remains something of a black box though, in part because of the challenges...
- This grant will aid the progression of ASHA-624 towards first-in-human clinical trials. Designed using the company’s PRISM drug design technology, it is a brain-penetrant intra-molecular glue inhibitor of The post Asha Therapeutics...
- The BLA is sought for treating NSCLC patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFR) who have received systemic therapies previously. Concurrently, the companies have The post AstraZeneca and...
- The $0.6m (4m yuan) deal, which will facilitate Lakeside’s entry into the medical logistics sector, is set to contribute an estimated $7m in annual revenues to the integrated The post Lakeside Holding agrees to acquires Hupan...
- The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid...
- Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or loss of muscle mass. The discovery...
- Immune cells are capable of detecting infections just like a sniffer dog, using special sensors known as Toll-like receptors, or TLRs for short. But what signals activate TLRs, and what is the relationship between the scale and nature of...
- ALT-B4 will be used for developing the subcutaneous formulation ENHERTU. As per the agreement, Daiichi Sankyo will gain global rights to utilise Alteogen’s ALT-B4, a human recombinant hyaluronidase The post Alteogen and Daiichi...
- Situated in Milton Park, near Oxford, the new 30,000ft2 facility is part of NEB’s wholly-owned subsidiary network. The site is designed to offer solutions for ambient molecular biology The post New England Biolabs opens new...
- Researchers at Uppsala University and KTH Royal Institute of Technology have developed a new form of precision medicine, an antibody, with the potential to treat several types of cancer. Researchers have managed to combine three...
- Even treated with the most advanced therapies, patients with glioblastoma - an aggressive brain cancer - typically survive less than two years after diagnosis. Efforts to treat this cancer with the latest immunotherapies have been...
- This epinephrine sublingual spray is designed for emergency situations. The FDA’s feedback could potentially lead the company to a New Drug Application (NDA) submission. The FDA-approved epinephrine prodrug The post Insignis...
- This partnership leverages SpectronRx’s advanced facilities for late-stage clinical and commercial supplies of the therapy. SpectronRx and Plus Therapeutics collaboration is set to accelerate nuclear medicine and improve The post...
- Scientists have uncovered how certain E. coli bacteria in the gut promote colon cancer by binding to intestinal cells and releasing a DNA-damaging toxin. The study, published in Nature, sheds light on a new approach to potentially reduce...
- Professor Meritxell Huch receives this year's Otto Bayer Award. The Otto Bayer Award is presented alternating with the Hansen Family Award every second year. The award recognizes leading scientists working in German-speaking countries...
- As the hunt for effective cancer therapies intensifies, some scientists are turning back to look at old drugs in a new light. The anti-malarial hydroxychloroquine is one such drug that has been "repurposed" to fight cancer. Despite its...
- "As tumors grow very quickly, consume a lot of oxygen and their vascular growth can't necessarily keep pace, they often contain areas that are poorly supplied with oxygen," explains Johannes Karges. These areas, often in the center of...
- GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from Chimagen for...
- A technological breakthrough by medical researchers at Tel Aviv University enabled the discovery of a cancer mechanism that prevents the immune system from attacking tumors. The researchers were surprised to find that reversing this...
- Patients with late-stage cancer often have to endure multiple rounds of different types of treatment, which can cause unwanted side effects and may not always help. In hopes of expanding the treatment options for those patients, MIT...
- Pharmaceutical scientists from the National University of Singapore (NUS) have identified and characterised a unique multidomain enzyme capable of catalysing two distinct types of reactions, both vital for making drug molecules. Natural...
- Researchers at Winship Cancer Institute of Emory University have identified a novel type of immune cell, called the stem-like CD4 T cell, that plays a pivotal role in anti-tumor immunity. The pre-clinical findings, published in Nature,...
- Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. This is the...
- New research from biologists at the USC Dornsife College of Letters, Arts and Sciences reveals that mifepristone, a drug best known for its use for ending early pregnancies, might also extend lifespan. The findings could pave the way for...
- Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower...
- Expanding access to new, highly effective weight-loss medications could prevent more than 40,000 deaths a year in the United States, according to a new study led by researchers at Yale School of Public Health and the University of...
- Since the passing of Professor Emeritus Alan Mackay-Sim AM in 2023, his ground-breaking legacy research is about to be realised with a Phase I human clinical trial commencing to test the efficacy and safety of the transplantation of...
- The inflammatory disease affects around one in 2,000 people in the US
- Results from a mid-stage of the candidate were recently published in the NEJM
- The skin disease affects an estimated 1% of the population in most studied countries
- The collaboration will first focus on developing products for long COVID and ME/CFS
- Researchers used a technique to identify specific molecular details of biotin-labelled proteins
- Around 60,000 people are diagnosed with pancreatic adenocarcinoma in the US every year
- The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals
- The drug could prevent conditions including diabetic eye and kidney disease in diabetes
- The Yellow Card Biobank will begin investigating direct oral anticoagulants such as apixaban
- The deal gives the company access to a candidate being evaluated in primary biliary cholangitis
- There are now more than 8,000 patients who are potentially eligible for treatment with Casgevy
- Approximately one in 10,000 people are affected by the genetic blood clotting disorder
- The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK
- F404 mutations combined with pre-existing mutations caused resistance to fulvestrant
- Both companies will leverage their autologous CAR-T cell therapy programmes
- Ten23 health expands former swissfillon facility in Visp, Switzerland jkeenan Mon, 03/28/2022 - 08:41
- Sobi to trim staff as Pfizer manufacturing contract ends early jkeenan Thu, 03/24/2022 - 08:40
- Epinephrine recall: Adamis pulls Symjepi injections for needle clogging risks aliu Wed, 03/23/2022 - 11:18
- Fujifilm makes yet another deal to jack up cell and gene therapy capacity kdunleavy Tue, 03/22/2022 - 21:13
- Takeda's Natpara relaunch bid falls flat as manufacturing concerns drag on jkeenan Tue, 03/22/2022 - 09:22